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Artemisinin-resistant malaria along the Thailand-Cambodian border is an important public health concern, yet mechanisms of
drug action and their contributions to the development of resistance are poorly understood. The pharmacokinetics and pharma-
codynamics of oral artesunate monotherapy were explored in a dose-ranging trial in an area of emerging artesunate resistance in
western Cambodia. We enrolled 143 evaluable subjects with uncomplicated Plasmodium falciparum malaria in an open label
study of directly observed artesunate monotherapy at 3 dose levels (2, 4, and 6 mg/kg of body weight/day) for 7 days at Tasanh
Health Center, Tasanh, Cambodia. Clinical outcomes were similar among the 3 groups. Wide variability in artesunate and dihy-
droartemisinin concentrations in plasma was observed. No significant dose-effect or concentration-effect relationships between
pharmacokinetic (PK) and parasite clearance parameters were observed, though baseline parasitemia was modestly correlated
with increased parasite clearance times. The overall parasite clearance times were prolonged compared with the clearance times
in a previous study at this site in 2006 to 2007, but this did not persist when the evaluation was limited to subjects with a compa-
rable artesunate dose (4 mg/kg/day) and baseline parasitemia from the two studies. Reduced plasma drug levels with higher pre-
sentation parasitemias, previously hypothesized to result from partitioning into infected red blood cells, was not observed in this
population with uncomplicated malaria. Neither in vitro parasite susceptibility nor plasma drug concentrations appeared to
have a direct relationship with the pharmacodynamic (PD) effects of oral artesunate on malaria parasites. While direct concen-
tration-effect relationships were not found, it remains possible that a population PK modeling approach that allows modeling of
greater dose separation might discern more-subtle relationships.
Oral artesunate (AS) is an important drug used in the control ofmultidrug-resistant Plasmodium falciparum malaria. However,
the mechanism of action for this class of drugs, known as the
artemisinins, and thus potential mechanisms for development
of drug resistance remain poorly understood. Semimechanistic
models of parasite dynamics have been proposed to explain the
potential effects of drug on parasite sequestration in unmea-
surable compartments (16, 18). Selective effects of drug on
early parasite ring stages were found to explain differences in parasite
clearance observed between patients treated in Thailand and Cam-
bodia using intrahost mathematical modeling of pharmacokinetic
(PK)-pharmacodynamic (PD) relationships (36). Autoinduction
of metabolism has been suggested for drugs in this class (15, 17),
representing a possible confounder to parasite-based mechanisms
of resistance. The current models provide only limited explana-
tions for artesunate resistance, creating an ongoing need for addi-
tional empirical data.
We recently reported evidence of artesunate resistance in ma-
laria parasites from patients treated in a clinical trial conducted in
western Cambodia in 2006 to 2007 (30, 31). This study showed
delayed parasite clearance times and reduced artemisinin drug
susceptibility in vitro in spite of what appeared to be therapeutic
drug levels. However, pharmacologic collection times in that
study were limited to 2 time points after dosing, prompting an
effort to conduct more-detailed analysis. A dose-ranging clinical
trial of artesunate monotherapy at 3 doses (2, 4, and 6 mg/kg of
body weight/day once daily for 7 days) was conducted to better
understand pharmacokinetic (PK)-pharmacodynamic (PD) rela-
tionships of oral artesunate monotherapy in 2008 to 2009 (7). The
rates of adequate clinical and parasitological responses (ACPR) in
all treatment arms to artesunate at 28 and 42 days were compara-
ble to those observed in previous oral artesunate monotherapy
studies in this geographic region (8, 9, 17, 26, 34). There were
prolonged parasite clearance times observed compared to the
clearance times in the study carried out in 2006, with more than
50% of patients remaining parasitemic 72 h after commencing
artesunate treatment. The pharmacokinetics and pharmacody-
namics of oral artesunate and dihydroartemisinin (DHA), its ac-
tive metabolite, were explored to test whether alterations in phar-
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macokinetics could explain the apparent changes in parasite
pharmacodynamics. We investigated dose-effect and concentra-
tion-effect relationships with key pharmacodynamic variables, in-
cluding parasite clearance and in vitro parasite drug susceptibility
to evaluate whether increasing the dose of oral artesunate might
improve pharmacodynamic responses by reducing the rate of
clinical failure or decreasing the parasite clearance time.
MATERIALS AND METHODS
Clinical study. The U.S. Army Medical Component, Armed Forces Re-
search Institute of Medical Sciences (AFRIMS), and the Center for Para-
sitology, Entomology and Malaria Control (CNM) in Cambodia con-
ducted an open label study of oral artesunate (AS) monotherapy in
Tasanh, Cambodia, from 2008 to 2009 (7) and compared the results to a
study conducted at the same site from 2006 to 2007 (30). Both studies
were approved by the Walter Reed Army Institute of Research institu-
tional review board (IRB) and the National Ethical Committee for Health
Research of Cambodia and complied with relevant federal guidelines and
institutional policies. Adult patients with uncomplicated Plasmodium fal-
ciparum malaria from the Samlot district of Battambang Province in
Cambodia were randomized into 3 groups of 2, 4, or 6 mg/kg of body
weight/day directly observed oral artesunate monotherapy for 7 days with
target treatment allocation of 150 subjects with a 2:1:2 ratio. The dose was
rounded up to the nearest 1/4 tablet, with quality control analysis of study
drug as described previously (7). However, the high-dose cohort (6 mg/
kg) was halted due to dose-limiting neutropenia after 28 patients had been
enrolled (6). Subjects were monitored for 42 days for clinical efficacy,
safety, pharmacokinetic (PK) analysis, and parasite molecular and in vitro
drug resistance phenotype characterization. Lean body mass (LBM) was
estimated using the following formulas: LBM  (1.10  weight)  128 
[weight2/(100  height)2] for men and LBM  (1.07  weight)  148 
[weight2/(100  height)2] for women. For the purposes of the present
analysis, subjects were categorized as late responders (LR) if they had
persistent fever and parasitemia beyond 72 h of therapy and late treatment
failures (LTF) if they had clinical and/or parasitological P. falciparum
malaria recurrence within the follow-up period.
Pharmacokinetics. PK blood samples were collected in heparinized
tubes on the first day of AS dosing (day 0) at times 0 (predose), 15, 30 min,
1, 2, 4, 6, 8 h, and on the 7th day of AS dosing (day 6) at times 0 (predose)
2, 4, and 6 h. Samples were collected on ice and centrifuged immediately,
and plasma was stored at 20°C for up to 2 weeks, followed by transfer to
our reference lab in liquid nitrogen with storage at 80°C until analysis.
AS and dihydroartemisinin (DHA) drug levels were determined by liquid
chromatography-mass spectrometry (LC-MS) as previously described
(38). The actual sample sizes for the pharmacokinetic analysis database
were 75, 40, and 28 subjects who received 2, 4, and 6 mg/kg of AS,
respectively. All late responders, late treatment failures, and neutro-
penia patients were included in the pharmacokinetic and pharmaco-
dynamic analyses.
Pharmacodynamics. Malaria whole-blood films for parasite density
were collected by finger stick and/or venipuncture 8 times in the first 24 h
(at 0, 2, 4, 6, 8, 12, 18, and 24 h) and then every 6 h until 2 negative smears
were obtained. Thick and thin smears were prepared with counts per 200
white blood cells (WBC) on a thick film or per 5,000 red blood cells (RBC)
on a thin film with a minimum of 200 oil immersion fields examined
FIG 1 Plasma drug concentration-time profiles of subjects included in the pharmacokinetic analysis. Artesunate (AS) concentrations are shown in red, while
dihydroartemisinin (DHA) concentrations are shown in blue. A total of 75, 40, and 28 subjects were given 2, 4, and 6 mg/kg AS, respectively.
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before a negative read was determined. Final outcome determination was
adjusted for species using PCR genotyping using merozoite-specific pro-
tein 1 (MSP1) , MSP2, and Glurp for all malaria recurrences using previ-
ously described methods (40). Fifty and 90% parasite clearance times
(PCT50 and PCT90, respectively) were calculated using curve-fitting anal-
ysis with GraphPad Prism, version 5 (La Jolla, CA).
In vitro parasite drug susceptibility. Enrolled subjects provided 8 ml
of blood in sodium heparin tubes for a histidine-rich protein 2 (HRP-2) ex
vivo drug susceptibility assay, and 50% inhibitory concentrations (IC50)
for each parasite isolate were calculated. Susceptibility was measured
against 6 drugs—artesunate (AS), dihydroartemisinin (DHA), lumefan-
trine (LUM), chloroquine (CQ), quinine (Q), and mefloquine (MQ). P.
falciparum isolates were plated directly onto malaria drug-coated plates
without prior culture adaptation, as previously described (7, 29).
Data analysis. (i) Pharmacokinetic analysis. Pharmacokinetic pa-
rameters were calculated using noncompartmental analysis (NCA) with
PK Solutions software, after determining that there was little difference
between NCA and a one-compartment model calculated using Phoenix
WinNonlin version 1.3 (Pharsight Corporation). The PK parameters de-
termined were the elimination half-life (t1/2), maximum concentration in
plasma by inspection (Cmax), time to reach Cmax (Tmax), the areas under
the concentration-time curve (AUC) from 0 h to  (AUC0 –), 0 to 6 h
(AUC0 – 6), 0 to 8 h (AUC0 – 8), and 2 to 6 h (AUC2– 6), the mean residence
time (MRT), the volume of distribution (V), and the clearance (CL). For
extravascular models, the fraction of dose absorbed cannot be estimated.
Therefore, V and CL for the models are actually V/F and CL/F where F is
the estimated fraction absorbed.
(ii) Pharmacodynamic analysis. The 100% parasite clearance time
(PCT100) was defined as the time from the start of treatment until the first
time the blood smear became negative for asexual parasites and remained
negative for 2 consecutive measurements. PCT50 and PCT90 were calculated
as the time to reduction of parasitemia to 50 and 90%, respectively, of the
baseline parasitemia value (P0). PCT50 and PCT90 were calculated by inter-
polation using a curve-fitting model in GraphPad Prism, version 5 (La Jolla,
CA). The PCT50 was calculated based on a dose-response relationship using a
4-parameter equation where Y  lower asymptote  (upper asymptote 
lower asymptote)/{1  10[(log PCT50  X)  Hill slope]} where Y is the number
of parasites per microliter at time X where X is the log time in hours.
PCT90 was calculated using the following equation: log PCT50  log
PCT90  (1  hill slope)  log [F/(100  F)] where F is equal to 10.
Parasite reduction ratios (percent parasite reduction ratio [%PRR]) were
calculated as 100 minus the percentage reduction from P0 at 24, 48, and 72
h after treatment using the formula 1  (Px/P0) where x is the number of
hours from time zero. Linear relationships using nonparametric correla-
tion tests were used to investigate the relationships between PK and PD
parameters. Parasite clearance rates were also calculated using previously
described methods (13), and compared with drug dose levels using one-
way analysis of variance (ANOVA).
(iii) Statistical analysis. Values of normally distributed data were ex-
pressed as means (95% confidence intervals [95% CI]) with standard
deviations and nonnormally distributed data as medians with inter-
quartile ranges (IQR). Means, medians, and/or geometric means were
compared using ANOVA for normally distributed data, with nonpara-
metric tests (Kruskal-Wallis) for nonnormally distributed data. For
continuous variable PK-PD relationships, Spearman’s correlation co-
efficients () were calculated using pairwise elimination for missing
case data, and multiple linear and logistic regression analysis were
performed using SPSS 16.0.
RESULTS
Pharmacokinetics. There was wide interindividual variability in
plasma AS and DHA concentrations at day 0 and day 6 with a
reduction in the AUC during the terminal elimination phase on
day 6 (between 146 and 150 h), as seen in Fig. 1. The pharmaco-
kinetic parameters for AS and DHA are shown in Table 1. Plasma
AS levels were low on day 6, preventing accurate PK parameter
calculations, so only day 0 values are shown. There was an approx-
imate 2-fold reduction in the AUC of DHA between day 0 and day
6 regardless of dose, when comparable concentration-time points
were compared (Table 2).
There were no significant differences in AS (not shown) or
DHA exposure seen with lean body mass by either dose adminis-
tered or sex (Fig. 2A and B). Linear dose proportionality of AUC
and Cmax were observed with increasing doses of artesunate (Fig.
2C). While there were increases in day 0 AS and DHA concentra-
tions by dose at 2, 4, and 6 mg/kg (Fig. 3A and B), there was no
difference between mean plasma concentrations of DHA at any
TABLE 1 Summary of overall pharmacokinetic parameters for subjects
taking oral artesunate for 7 days
PK parameter
Geometric mean value for subjects
given the following dose of AS:
P valued2 mg/kg 4 mg/kg 6 mg/kg
AS on day 0a
t1/2 (h) 0.489 0.499 0.461 0.827
Tmax (h) 0.482 0.518 0.640 0.366
Cmax (g/liter) 83.1 237 374 0.0001
AUC0–8 (g · h/liter) 91.2 279 453 0.0001
MRT (h) 1.07 1.06 1.17 0.749
V/F (liter/kg) 14.2 10.1 8.56 0.051
CL/F (liter/h/kg) 20.1 13.9 12.9 0.0001
DHA on day 0b
t1/2 (h) 0.838 0.913 1.13 0.170
Tmax (h) 1.26 1.15 1.44 0.310
Cmax (g/liter) 554 1,515 2,129 0.0001
AUC0–8 (g · h/liter) 1,331 3,854 5,989 0.0001
MRT (h) 2.06 2.21 2.84 0.008
DHA on day 6c
t1/2 (h) 0.799 0.851 0.843 0.186
Tmax (h) 2.08 2.11 2.17 0.555
Cmax (g/liter) 196 497 875 0.0001
AUC0–8 (g · h/liter) 481 1267 2218 0.0001
MRT (h) 2.53 2.67 2.64 0.144
a For the artesunate (AS) pharmacokinetic (PK) parameters for subjects given AS on
day 0, 75, 40, and 28 subjects were given 2, 4, and 6 mg/kg of AS, respectively.
b For the dihydroartemisinin (DHA) PK values on day 0, 75, 40, and 27 subjects were
given 2, 4, and 6 mg/kg of AS, respectively. One subject was excluded from the 6-mg/kg
AS group because of an outlier value.
c For the DHA PK values on day 0, 73, 38, and 25 patients were given 2, 4, and 6 mg/kg
of AS, respectively. The sample size decreased for all three groups because there are no
follow-up data for two subjects.
d P value for Kruskal-Wallis one-way ANOVA.
TABLE 2 Changes in mean area under the curve for DHA between days









a AUC2–6 AUC0–6 AUC2–6 AUC0–6 AUC2–6
2 73 1,067 652 554 330 1.93 1.97
4 38 2,853 1,801 1,263 775 2.26 2.33
6 25 4,850 3,221 1,394 1,472 2.03 2.19
a AUC0 – 6 (area under the concentration-time curve from 0 to 6 h) as calculated from
time points at 0, 2, 4 and 6 h on day 0 as they were collected on day 6 for purposes of
comparison between day 0 and day 6 only.
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time point between those subjects who had persistent para-
sitemia at 72 h and those who did not (Fig. 3C). This lack of
effect remained even after corrections for baseline parasitemia
were made.
Pharmacodynamics. (i) Dose-effect relationships. There was
continuous reduction in parasitemia over the first 24 h following
the first dose of each drug, persisting well beyond the effective
clearance (4.5 half-lives) of AS at 2.94 h and DHA at 4.67 h
(Fig. 4A). Figure 4B plots median concentration versus time-spe-
cific parasite reduction ratios (percent parasite reduction ratio
[%PRR]) at each time point for both AS and DHA at the 3 dose
levels. Regardless of dose, 50% PRR was reached on the first day at
approximately 8 to 12 h. There was no apparent dose-effect or
concentration-effect relationship of the drug on either clinical
outcome or parasite clearance. This was true not only for parasite
clearance times but also parasite clearance rates (not shown). As
previously reported, there were no clinically or statistically signif-
icant differences in 28- or 42-day treatment outcomes between
dosing groups with 2 subjects each having late treatment failure
(LTF) in the 2- and 6-mg/kg groups and 1 subject with LTF in the
4-mg/kg group (7). The mean times to 50% (not shown) and 90%
parasite clearance (PCT90) were not significantly different by dos-
ing group compared by Kaplan-Meier survival analysis (Fig. 5A).
Mean values were used for this analysis due to normal distribution
of parasite clearance time data.
(ii) Concentration-effect relationships. There was variability
in the concentration-time curves for patients classified as late re-
sponders and late treatment failures (LR and LTF, respectively),
particularly with LR (Fig. 6). Notably, none of the LR went on to
become an LTF. Only 1 of the 5 LTF subjects had AS and DHA
drug concentrations that were more than 1 standard deviation
below the mean for their respective dosing group. There were no
statistically significant correlations between pharmacokinetic
variables, including AUC, Cmax, or clearance of AS or DHA with
pharmacodynamic variables, including PCT50, PCT90, or PCT100
or parasite reduction ratio (PRR) at 12, 24, 48, or 72 h using
nonparametric correlation analysis (Spearman’s  [Table 3]). We
compared the ratios of AUC and Cmax for DHA (in nanograms per
milliliter) to the IC50 for DHA (in ng/ml) on day 0 to see whether
the failures had lower values. However, no correlations were
found for these ratios, either for the study population as a whole or
for LTF or LR patients.
(iii) Pharmacodynamics and in vitro drug susceptibility.
There were modest but statistically significant correlations be-
tween the pharmacodynamic parasite clearance variables and in
vitro drug resistance of fresh parasite isolates as measured by IC50
collected at time zero using an HRP-2 assay against 6 drugs (AS,
DHA, CQ, LUM, Q, and MQ). PCT50 and PCT100 were modestly
correlated with increases in the IC50s of both AS (  0.242 and
0.223, respectively) and DHA (  0.200 and 0.222, respectively),
and there was an inverse correlation between IC50 and PRR72 ( 
0.217 for DHA and 0.170 for AS). Conversely, higher baseline
parasitemia (P0) correlated with modest but significantly in-
creased IC50s for AS (  0.294), DHA (  0.262), and CQ ( 
0.181), and there was a modest inverse correlation with the IC50 of
Q (  0.118) (Table 3). We compared the ratios of AUC and
Cmax for DHA (in ng/ml) to the IC50 value for DHA (in ng/ml) on
day 0 to see whether failures had lower values. However, no cor-
FIG 2 (A and B) There was no relationship between lean body mass (LBM) and drug concentrations in blood based on AUC0 – 8 of DHA by dose (A) or
sex (B) (31 females and 112 males). (C) Linear dose proportionality of geometric mean AUC and Cmax (not shown) was seen with increasing artesunate
doses.
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relations between these ratios were found, either for the study
population as a whole or LTF or LR patients.
(iv) Effects of baseline parasitemia. There was a modest cor-
relation between PCT50 and PCT100 and parasitemia at baseline
(  0.204 and 0.377, respectively, and P  0.001 [Table 3]). The
geometric mean P0 was 2-fold higher in subjects who had persis-
tent parasitemia at 72 h (20,914 parasites/l) than those who had
cleared parasites at 72 h (8,991 parasites/l) (P  0.002). There
FIG 3 (A and B) Geometric mean plasma AS and DHA concentration-time curves by dose. (C) Geometric mean concentration-time points are plotted against
parasite clearance time (PCT) greater or less than 72 h.
FIG 4 (A) Parasite clearance as the mean percentage of baseline values over the first 24 h for the 3 dose groups. The broken lines show the median concentration-
time profiles of AS and DHA. The geometric mean half-life (t1/2) and 4.5 half-life values appear in the accompanying table below the graph. (B) Concentration-
effect relationships on percent parasite reduction (percent parasite reduction ratio [%PRR]) for AS and DHA at the 3 dose levels.
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was no measurable effect of P0 on PK parameters of AS or DHA
with the exception of a small (though statistically significant) in-
verse effect on V/F.
Key results from studies conducted at the Tasanh site in Cam-
bodia in 2006 (30) and 2009 (7) are compared in Table 4 for all
subjects and for only those subjects with comparable dose (4 mg/
kg) and enrollment parasitemia (between 1,000 and 100,000 par-
asites/l). The 2006-2007 and 2008-2009 studies had different
enrollment criteria for baseline P. falciparum parasitemia—100 to
100,000 parasites/l versus 1,000 to 200,000 parasites/l, respec-
tively. The median parasite density on enrollment was signifi-
cantly higher in 2009 (P value  0.01). Though parasite clearance
times (PCT) and the proportion of patients still parasitemic at 72
h were significantly different between the two overall study pop-
ulations, when comparing only patients taking 4 mg/kg AS with
between 1,000 and 100,000 parasites/l at enrollment, the differ-
ences in parasite clearance times were no longer statistically sig-
nificant. This was also true for the log rank test for this comparable
patient subset when Kaplan-Meier survival analysis (not shown)
was applied to the patient population that was still parasitemic
over the first 72 h (Table 4).
DISCUSSION
In a study of 143 patients in western Cambodia receiving 7 days of
directly observed oral artesunate monotherapy, we found that
plasma drug levels of artesunate and DHA and corresponding
rates of parasite clearance were highly variable in this population.
Where we had expected to see an increase in parasite clearance
times and/or relative reductions in parasite burdens with in-
creasing drug concentrations, we did not find clear relation-
ships between plasma drug concentration or PK parameters on
pharmacodynamic efficacy variables, including clinical out-
comes, parasite clearance times, or relative reductions in para-
sitemia. Despite this variability, the 28- and 42-day treatment ef-
ficacies of all 3 dose levels were equal to or higher in some cases
than those previously reported for various 5- to 7-day regimens of
FIG 5 (A) Kaplan-Meier survival analysis of time to 90% parasite clearance. The x axis represents the time to reach 90% parasite clearance. (B) Mean times to
50% or 90% parasite clearance (PCT50 or PCT90) by the log rank test at the 3 doses of artesunate. The mean, standard deviation (SD), and 95% confidence interval
(95% CI) values are shown.
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artesunate monotherapy, which have ranged between 85 and
100% in Southeast Asia and Africa (1, 8, 9, 17, 26, 34). Parasite
clearance times were longer in our study than those reported in
previous monotherapy studies in the region (PCT range, 40 to 55
h), including previous data from the Tasanh site in Cambodia in
2006 (30), and similar to those reported from a concurrent study
in Pailin, Cambodia (12).
Distinguishing the host, pharmacokinetic, and intrinsic para-
site factors responsible for resistance remains a daunting chal-
lenge. Semimechanistic models of parasite dynamics have been
developed to explain the potential effects of drug on parasite se-
questration in unmeasurable compartments (18). Development
of similar models for our data set may shed further light on the
lack of an observed relationship on the plasma drug levels and
parasite clearance based on light microscopy. A recent PK-PD
model demonstrating selective effects of drug on early parasite
ring stages in Southeast Asia helped to identify a source for focus
of further investigation of resistance mechanisms (36). It is possi-
ble that developing similar modeling approaches would reveal
subtle relationships in our data set that were not apparent with the
limited approach taken here.
While dose-response effects with AS monotherapy have been
observed previously (12), our findings indicate a lack of dose re-
sponse between 2, 4, and 6 mg/kg/day of oral artesunate. Despite
the lack of dose response, we found evidence for a postantibiotic
effect with persistent reduction in parasitemia over 24 h after both
AS and DHA had been effectively cleared from the body. This
suggests that artemisinin action against blood stage parasites may
be dependent on concentration rather than time. This is sup-
ported by hysteresis seen in our data set with a lag following the
peak concentration to the onset of maximal drug effect. This
would indicate that pharmacodynamic effects could be increased
by increasing the dose to achieve a higher Cmax. However, this
approach was not supported by our data which showed that in-
creasing the artesunate dose to 6 mg/kg did not influence clinical
or parasitological outcomes, despite achieving higher Cmax. Alter-
native explanations for this postantibiotic effect would include the
persistence of drug in unmeasured or unmeasurable compart-
ments or persistent activity of drug at concentrations below the
limit of quantification. The former hypothesis would suggest that
AS and DHA at the doses used were in excess of the amount
needed to bind parasitized erythrocytes at the parasitemias ob-
served in this population with uncomplicated P. falciparum ma-
laria. This finding is supported by a prior prediction that increases
in parasite clearance responses are unlikely at oral doses above 2
mg/kg, based on single-dose maximum effect (Emax) modeling
(2). Parasite dormancy has also been suggested in animal studies
as a possible explanation for parasite recrudescence despite appar-
ently adequate drug levels (21).
Parasitemia at baseline had an impact on the pharmacodynam-
ics of parasite clearance, with a positive correlation between P0
and parasite clearance times, as well as a loss of statistical differ-
ences in the parasite clearance times found in our 2006 and 2009
Tasanh studies when subjects with comparable drug doses and
baseline parasitemia were compared. While the loss of significance
in our data set could be attributable to sampling effect (the num-
ber of subjects taking the 4-mg/kg dose was reduced from 98 to 80
volunteers in our analysis), this finding has been reported previ-
ously (20) and suggests that baseline parasitemia is an important
methodological consideration that should be controlled for when
interpreting parasite clearance data in clinical trials of artemis-
inins.
There was a modest influence of intrinsic parasite artemisinin
susceptibility ex vivo (IC50) on pharmacodynamic outcomes, but
an equal influence of baseline parasitemia (P0) on the in vitro
results by nonparametric correlation analysis. Using a ratio of
pharmacokinetic parameters and IC50 did not reveal a relation-
ship with parasite reduction or clearance. Given the effects of P0
on in vitro drug susceptibility test results with modest but signifi-
cant correlations seen between increasing P0 and increasing IC50,
FIG 6 Detailed plasma concentration-time curve plots for 7 subjects classified as late responders (LR) and 5 subjects classified as late treatment failures (LTF).
Notably, no LR subjects went on to become LTF. Subject identification (ID) numbers are followed by artesunate dosing groups (AS2, AS4, and AS6 for artesunate
doses of 2, 4, and 6 mg/kg, respectively). The lower limit of quantitation (LLOQ) by LC-MS for DHA is shown as a dotted line.
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this relationship should be taken into account when interpreting
in vitro field isolate data.
Despite a lack of dose response for antimalarial activity, arte-
sunate did produce a dose-limiting neutropenia in 5 of 28 sub-
jects, as reported previously (6). It is unclear at this time if the
effect on the neutrophil could be reduced by using higher doses
over shorter periods, but given the lack of additional efficacy at
higher doses, it does not appear that this strategy is likely to be
effective.
Pharmacokinetic data were comparable to the previously ob-
served results following oral dosing with artesunate in patients
with uncomplicated P. falciparum malaria (4, 10, 32, 33), with
somewhat higher values for PK parameters, including AUC and
Cmax than those seen in studies of healthy volunteers (5, 33, 39).
This could be attributable in part to a lack of standardization in PK
analysis methods among laboratories. Oral data presented here
contrast with recently reported intravenous (i.v.) data for good
manufacturing process (GMP) intravenous artesunate, which
found not only rapid hydrolysis of AS to DHA but also much higher
Cmax values for AS than for DHA (22). The comparison suggests high
first pass metabolism of AS when given by the oral route.
Our pharmacokinetic data revealed a reduction in drug expo-
sure over 7 days of oral therapy, similar to previous reports. Au-
toinduction of metabolism has been suggested for drugs in this
class (16, 17), representing a possible confounder to parasite-
based mechanisms of resistance. Though some reports have at-
tributed the observed decline in levels to the autoinduction of
metabolism by artesunate (17), previous data from Southeast Asia
suggest that this phenomenon may in fact be attributable to a
transition from the infected to uninfected state over the course of
therapy. Studies of healthy volunteers revealed reduced conver-
sion of AS to DHA, reduced plasma drug levels, and little change
in drug exposure over the course of 5 to 7 days of monotherapy
compared to malaria patients where increased initial drug levels
and a pronounced decrease in exposure over the course of therapy
was seen (11, 37, 39). This suggests that host pharmacokinetics
may be influenced by the presence of the parasite itself, though
the mechanisms for this remain unproven. It is unclear whether this
is a result of changes in drug metabolism, protein binding, drug
distribution, and/or interactions with infected red blood cells that
occur in malaria patients. Both reduced conversion of AS to DHA
and reductions in penetration into the uninfected red blood cell
could be possible explanations. Further, it remains unclear
whether the observed reductions in drug concentration over the
course of AS monotherapy are enough to account for treatment
failures.
Our data add further evidence to the hypothesis that the site of
drug action and appropriate place to measure pharmacokinetics





Parasite clearance time Parasite reduction ratio
P050% 90% 100% 24 h 48 h 72 h
Parasite density at time zero (P0) 0.204 0.025 0.377 0.002 0.028 1.410 1.000
PK parameters
AS on day 0
AUC0–8 0.125 0.092 0.067 0.054 0.020 0.049 0.052
Cmax 0.076 0.072 0.058 0.450 0.004 0.045 0.051
CL/F 0.058 0.007 0.045 0.032 0.119 0.155 0.064
V/F 0.050 0.027 0.006 0.007 0.015 0.067 0.035
DHA on day 0
AUC0–8 0.125 0.095 0.091 0.068 0.068 0.029 0.073
Cmax 0.079 0.077 0.088 0.034 0.064 0.014 0.064
CL 1.010 0.080 0.090 0.071 0.054 0.048 0.086
V/F 0.088 0.026 0.060 0.015 0.052 0.012 0.191
DHA on day 6
AUC 0.027 0.068 0.122 0.068 0.087 0.035 0.014
Cmax 0.010 0.057 0.120 0.063 0.077 0.039 0.013
CL 0.102 0.054 0.044 0.017 0.018 0.037 0.042
V/F 0.034 0.040 0.022 0.008 0.053 0.013 0.087
In vitro drug susceptibility (IC50
b)
DHA 0.200 0.117 0.223 0.104 0.098 0.217 0.262
AS 0.242 0.157 0.223 0.118 0.073 0.170 0.294
LUM 0.130 0.015 0.012 0.009 0.023 0.020 0.090
CQ 0.057 0.060 0.041 0.092 0.047 0.042 0.181
Q 0.178 0.149 0.114 0.123 0.093 0.108 0.118
MQ 0.122 0.040 0.050 0.006 0.029 0.032 0.013
a Spearman’s correlation coefficients () of the indicated pharmacokinetic or parasitological parameter compared to the pharmacodynamic outcomes expressed as 50, 90, and 100%
parasite clearance times and parasite reduction ratios at 24, 48, and 72 h. Statistically significant correlations are highlighted in boldface type (P  0.05).
b IC50s are 50% inhibitory drug concentrations in vitro.
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may be within the erythrocyte. The formation of artemisinin ad-
ducts both with malaria parasite proteins and the membranes of
disrupted but not intact red blood cells have been described pre-
viously (3, 19, 28). Further, selective uptake and concentration of
artemisinins within malaria parasite-infected red blood cells is
well documented, with many-fold-higher partition coefficients
for infected red blood cells compared to uninfected cells, where
partitioning of AS and DHA is only roughly 70% that of plasma
(24, 25). This may be due to increases in directional transportation
or intracellular binding (e.g., interactions with the malaria para-
site) across infected red blood cell membranes or the effects of
intracellular pH on drug ionization (14, 15, 27). Given that AS and
DHA concentrate in infected red blood cells at many-fold-higher
concentrations compared to uninfected cells, it might be expected
that higher parasitemias would correlate with lower plasma drug
levels due to partitioning into a currently unmeasurable storage
pool within the red blood cells. Unfortunately, a validated nonra-
dioactive method for measuring red blood cell drug levels remains
elusive. Increased baseline parasitemias did not correlate with re-
duced plasma drug levels in our study, though it has been postu-
lated that a clinically significant effect on PK parameters would be
likely to occur only at very high levels of parasitemia (5% or
greater) not generally seen in uncomplicated malaria (23). A prior
review of mass balance studies would also argue against this pos-
sibility (35).
A limitation of our PK analysis was omission of an interim
collection point between the 0- and 2-h time points on day 6, so
AUC over the period of peak drug concentration could not be
compared accurately. While some have fitted a one-compartment
model for DHA, we found little difference in individual PK pa-
rameters between a one-compartment analysis (not shown) and a
noncompartmental analysis. Our analysis would be strengthened
by a modeling approach, particularly to address the possibility
that the dose levels selected for the study were not sufficiently
different to distinguish concentration-dependent pharmacody-
namic effects on the malaria parasite. These limitations may have
impacted our ability to detect underlying relationships where one
truly existed.
The apparent lack of relationship between plasma pharmaco-
kinetic and pharmacodynamic outcomes raises a question regard-
ing the utility of routinely collecting these data in clinical trials.
However, given the paucity of overall understanding of the mech-
anisms of action or resistance to artemisinins, further clinical data
are clearly needed to add potential iterative validity to existing
models. Improved study design methods, including the use of
adaptive protocols, and a Bayesian approach to trial design using
pretrial simulations based on existing data may help to improve
understanding of the pharmacology of this important class of
drugs. The relationship between intraerythrocytic drug levels and
pharmacodynamic outcomes is of particular interest and likely to
yield more insight into how this class of drugs works.
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TABLE 4 Baseline characteristics and clinical and parasitological responses in two studies conducted at the Tasanh site in Cambodiaa
Baseline characteristic or clinical or
parasitological response
Median (interquartile range) for all patients
enrolled and randomized to 4 mg/kg AS for 7
days
P value
Median (interquartile range) for only patients
randomized to 4 mg/kg with a parasite density of
1,000 to 100,000/l
P value
Tasanh site in 2006
(n  60)
Tasanh site in 2009
(n  38)
Tasanh site in 2006
(n  45)
Tasanh site in 2009
(n  35)
Baseline characteristics
Age (yr) 29.0 (20.0–44.0) 22.0 (20.0–36.0) 0.10 27.0 (20.0–41.0) 22.0 (20.0–38.0) 0.31
Temp (°C) 38.0 (37.0–38.9) 38.1 (37.7–39.1) 0.12 38.0 (37.2–39.2) 38.1 (37.6–39.2) 0.51
Parasite density (no. of cells/l) 4,325 (982–18,643) 24,791 (6,714–51,498) <0.01 6,562 (3,892–33,452) 23,531 (6,389–39,393) 0.03
IC50 vs dihydroartemisinin concn
(g/liter)
1.16 (0.79–1.54) 2.59 (1.52–3.99) <0.01 1.19 (0.82–1.53) 2.59 (1.49–4.04) 0.01
Clinical and parasitological responses
Cmax of dihydroartemisinin
(g/liter)
1,226 (744–1,845) 1,467 (889–2,126) 0.25 1,345 (942–1,928) 1,468 (894–2,184) 0.69
Patients with adequate clinical and
parasitological responses (%)
93.3 94.7 0.78 91.1 94.4 0.57
Fever clearance time (h) 23.8 (10.1–30.1) 17.6 (9.65–28.8) 0.46 22.9 (10.0–29.4) 17.6 (10.0–29.2) 0.73
Parasite clearance time (h) 62.0 (38.0–86.6) 78.0 (64.4–96.1) <0.01 66.4 (43.0–91.0) 78.0 (61.5–96.1) 0.18
Patients with persistent parasitemia
after 72 h of treatment (%)
31.7 57.9 0.01 42.2 57.1 0.18
P value for log rank test of Kaplan-
Meier survival analysis
P  0.02 P  0.41
a Two studies were conducted at the Tasanh site in Cambodia in 2006 (30) and 2009 (7). Here we compare the values for baseline characteristics and clinical and parasitological
responses controlling for dose and enrollment parasitemia. Statistically significant differences are highlighted in boldface type with P values calculated by the Mann-Whitney U test
or by the chi-squared and Fisher’s exact tests where proportions were compared between treatment groups.
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official or as reflecting the views of the Department of the Army or the
Department of Defense.
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